Rezolute (RZLT) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
11 Jan, 2026Opening remarks and agenda
The meeting was called to order and webcast live, with instructions for virtual participation and Q&A provided.
The agenda included election of directors, auditor ratification, executive compensation, share increase, stock incentive plan amendment, and potential adjournment.
Board and executive committee updates
Six directors were nominated for election as detailed in the proxy statement.
Shareholder proposals
Proposals included electing directors, ratifying the auditor, approving executive compensation, increasing authorized shares, amending the stock incentive plan, and potential adjournment.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Rezolute
- Net loss widened to $22.8M; cash and investments at $132.9M, with key trials ongoing.RZLT
Q2 202612 Feb 2026 - Antibody therapy for hyperinsulinism shows strong efficacy and targets rare disease markets.RZLT
Guggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026 - Ersodetug offers a novel solution for severe hypoglycemia in rare HI, targeting a $1B+ market.RZLT
Corporate Presentation9 Jan 2026 - Phase III data for a universal hyperinsulinism therapy expected in December, with BLA filing mid-2026.RZLT
Morgan Stanley 23rd Annual Global Healthcare Conference31 Dec 2025 - Registration enables resale of 4.5 million shares by current investors, not a new capital raise.RZLT
Registration Filing16 Dec 2025 - Late-stage metabolic disease therapies advance, $6M raised, 4.5M shares registered for resale.RZLT
Registration Filing16 Dec 2025 - Resale registration for 1.3M shares from a $4.2M private placement; lead drug in Phase 3 for rare HI.RZLT
Registration Filing16 Dec 2025 - Phase III Sunrise/sunRIZE study failed to show significant efficacy over placebo.RZLT
Study Result12 Dec 2025 - Late-stage antibody therapy targets severe hypoglycemia in rare HI, with $1B+ market potential.RZLT
Corporate Presentation11 Dec 2025